Mentover SRL
3.2 FTEThe score of Mentover shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -51 % Total assets +59 % Headcount (avg FTE) +60 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Mentover's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 53,864 € | ||||
| Equity | 45,044 € | ||||
| Cash | 90,799 € | ||||
| EBITDA | 192,717 € | ||||
| Total assets | 981,994 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 15 Jul 2026
- Year ended 31 Dec 2024filed on 09 Jul 2025
- Year ended 31 Dec 2023filed on 23 Jul 2024
- Year ended 31 Dec 2022filed on 28 Aug 2023
- Year ended 31 Dec 2021filed on 19 Aug 2022
Mentover's financial analysis
- Solvency4.6%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Mentover
Mentover's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0668.692.363
- VAT number
- BE0668692363
- Peppol
- Registered · 0208:0668692363 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 03 Jan 2017
- Registered office
- 2060 Antwerp
- Size
- Micro · 3.2 FTE
- Latest accounts
- 2025 · filed on 15 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Mentover (SRL) has been based in Antwerp since 2017, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 53,864 € and equity of 45,044 €; its revenue is not published. With 3.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 4.6%, below the median of its sector (44.2%).
Companies similar to Mentover
Companies in the same business, of comparable size and area, outside its group.
- Apoteek Ackerman A. Retail sale of pharmaceutical products Ghent · balance sheet 981,775 €
- Apotheek Vloemans Retail sale of pharmaceutical products Brasschaat · balance sheet 982,280 €
- Pharmacie Classen Retail sale of pharmaceutical products Verviers · balance sheet 984,256 €
- Pharmasambre Retail sale of pharmaceutical products Sambreville · balance sheet 977,337 €
- DE Pourcq Farma Retail sale of pharmaceutical products Mechelen · balance sheet 987,151 €
- Goedam Retail sale of pharmaceutical products Beveren-Kruibeke-Zwijndrecht · balance sheet 987,673 €
- Pharmaplus Invest Retail sale of pharmaceutical products Forest · balance sheet 976,007 €
- Medithera Retail sale of pharmaceutical products Rixensart · balance sheet 972,011 €
Frequently asked questions about Mentover
What is the revenue of Mentover?
Mentover files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Mentover?
In Belgium, the VAT number is the company number prefixed with BE: BE0668692363 for Mentover, if the company is VAT-registered. Its company number (CBE) is 0668.692.363.
Where is the registered office of Mentover?
According to the CBE register, the registered office of Mentover is in 2060 Antwerp.
What is the equity of Mentover?
At the close of the 2025 financial year, the equity of Mentover amounts to 45,044 €, a solvency of 4.6% of total assets.
How many people work at Mentover?
3.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Mentover?
The register lists 2 active mandates at Mentover. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Mentover
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →